Once they have an approval I believe that off label use in Rett's is very probable. The key is having sufficient anecdotal evidence for insurance to pay for the drug. In time another trial, that isn't flawed, will gain full approval in Rett's IMHO. Gary
100% agree Tschussman. I only wish Anavex had believed in themselves as much as we did. Now they know and should be less conservative with our money. The admission at the AGM last Spring that they had underspent on Rett and planned on a fully-sized Rett trial was heartening. The fact that they never ran it is extremely frustrating but at least they seemed to agree that trial size and design need to trump reluctance to spend.
Market Data 
Markets 
AI
